Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs
- PMID: 23541541
- PMCID: PMC3815451
- DOI: 10.1016/S0140-6736(13)60104-X
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs
Abstract
Antiretroviral therapy for HIV infection needs lifelong access and strict adherence to regimens that are both expensive and associated with toxic effects. A curative intervention will be needed to fully stop the epidemic. The failure to eradicate HIV infection during long-term antiretroviral therapy shows the intrinsic stability of the viral genome in latently infected CD4T cells and other cells, and possibly a sustained low-level viral replication. Heterogeneity in latently infected cell populations and homoeostatic proliferation of infected cells might affect the dynamics of virus production and persistence. Despite potent antiretroviral therapy, chronic immune activation, inflammation, and immune dysfunction persist, and are likely to have important effects on the size and distribution of the viral reservoir. The inability of the immune system to recognise cells harbouring latent virus and to eliminate cells actively producing virus is the biggest challenge to finding a cure. We look at new approaches to unravelling the complex virus-host interactions that lead to persistent infection and latency, and discuss the rationale for combination of novel treatment strategies with available antiretroviral treatment options to cure HIV.
Copyright © 2013 Elsevier Ltd. All rights reserved.
References
-
- Hocqueloux L, Prazuck T, Avettand-Fenoel V, Lafeuillade A, Cardon B, Viard J-P, et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS. 2010;24(10):1598–601. - PubMed
-
- Lodi S, Meyer L, Kelleher A, Rosinska M, Ghosn J, Sannes M, et al. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Archives of Internal Medicine. 2012;172(16):1–4. - PubMed
-
- Goujard C, Girault I, Rouzioux C, Lécuroux C, Deveau C, Chaix M, et al. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antivir Ther. 2012;17(6):1001–9. - PubMed
-
- Hutter G, Nowak D, Mossner M, Ganepola S, Müssig A, Allers K, et al. Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation. New England Journal of Medicine. 2009;360(7):692–8. - PubMed
-
- Allers K, Hütter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, et al. Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood. 2011;117(10):2791–9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P01 AI080193/AI/NIAID NIH HHS/United States
- U19AI096109/AI/NIAID NIH HHS/United States
- R01 AI047745/AI/NIAID NIH HHS/United States
- K24 AI069994/AI/NIAID NIH HHS/United States
- R21 AI047745/AI/NIAID NIH HHS/United States
- AI306214/AI/NIAID NIH HHS/United States
- R56 AI047745/AI/NIAID NIH HHS/United States
- UM1 AI069432/AI/NIAID NIH HHS/United States
- AI080193/AI/NIAID NIH HHS/United States
- U19 AI096109/AI/NIAID NIH HHS/United States
- AI047745/AI/NIAID NIH HHS/United States
- U01 AI069432/AI/NIAID NIH HHS/United States
- AI74621/AI/NIAID NIH HHS/United States
- DP1 DA028871/DA/NIDA NIH HHS/United States
- U19 AI096113/AI/NIAID NIH HHS/United States
- AI69432/AI/NIAID NIH HHS/United States
- P01 AI074621/AI/NIAID NIH HHS/United States
- AI096113/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical